abbvie_0

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

pharmafile | May 20, 2019 | News story | Research and Development, Sales and Marketing |ย ย AbbVie, Cancer, Depatux-M, glioblastoma, pharma, trial failureย 

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed glioblastoma (GBM) in patients whose tumours have epidermal growth factor receptor (EGFR) amplification, after it was identified in an interim analysis that the therapy presented no survival benefit to patients.

The disappointing news comes after an Independent Data Monitoring Committee (IDMC) discovered that the drug, when combined with the standard regimen of radiation and temozolomide, lacked survival benefit compared to placebo, and thus recommended that the trial be stopped.

“Glioblastoma patients and their caregivers face a devastating disease for which there are few therapeutic options. While we are disappointed that Depatux-M did not demonstrate a survival benefit in the INTELLANCE-1 study, we remain committed to discovering and developing therapies to address some of the most debilitating cancers,” explained Dr Michael Severino, Vice Chairman and President at AbbVie.

Advertisement

The company also announced that enrolment has been placed on hold for all ongoing studies involving Depatux-M.

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

nerve-cell-2213009_960_720

Central nervous system cancer metastases โ€“ the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europeโ€™s first XSeed Labs to advance AI-powered antibody design

BioMed X and Servier have announced the launch of Europeโ€™s first XSeed Labs research project, …

The Gateway to Local Adoption Series

Latest content